Efficacy of Intralesional Antigen Versus Measles, Mumps, and Rubella Vaccine Versus Topical Podophyllin in Treatment of Resistant Genital Warts.

Background: No single treatment is ideal for genital warts with high rate of resistance using conventional modalities as topical podophyllin; however, several intralesional immunotherapies are being tested nowadays, with variable results. In this study, we compared the safety and efficacy of treating resistant and recurrent genital warts by 2 intralesional immunotherapies [ antigen and measles, mumps, and rubella (MMR) vaccine] and compared them with topical podophyllin.

Patients/methods: A total of 45 patients with resistant or recurrent genital warts were enrolled in this study. Size and number of warts were detected in each patient, patients were divided into 3 groups. Group A injected with intralesional antigen. Group B with intralesional MMR vaccine. Group C were treated with topical 25% podophyllin. Patients received a session every 2 weeks for 3 treatment sessions.

Results: With regard to the reduction in size and number of all warts, the best response was obtained in antigen group where 46.7% showed complete clearance and 40% showed partial response followed by MMR group and the last was the podophyllin group, with no significant difference between them. Complete clearance of mother warts was noticed in 86.7% of group, 53.3% in MMR group, and last 40% in podophyllin group, with a significantly better response in the group ( = .027).

Conclusion: Both intralesional antigen and MMR vaccine are simple, safe, and effective treatment options with comparable results and better response than topical podophyllin.